Drug intelligence / Profile preview

HGP1406

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HGP1406 is a therapeutic agent investigated primarily in bioequivalence studies, notably compared to HIP1302, in healthy male volunteers. The specific active ingredient, mechanism of action, and primary indication for HGP1406 are not publicly disclosed as of the latest available data. It is being researched as a pharmaceutical product and has undergone clinical evaluation for safety and pharmacokinetics. The developer associated with clinical trials involving HGP1406 is Hanmi Pharmaceutical Company Limited[1][2][5].

Beyond the preview

Go deeper on HGP1406.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HGP1406.

Explore the full profile